The kynurenine pathway relates to post‐acute COVID ‐19 objective cognitive impairment and PASC
Annals of Clinical and Translational Neurology · 2023
DOI: 10.1002/acn3.51825 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2023. Verfasst von Lucette A Cysique und 15 weiteren Autor:innen. Beteiligte Einrichtung: Peter Duncan Neuroscience Research Unit, St. Vincent's Centre for Applied Medical Research, Darlinghurst, New South Wales, Australia. Hauptthemen laut MEDLINE: COVID-19, Cognitive Dysfunction. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Objective
To determine the prevalence and natural history of post‐acute COVID‐19 objective cognitive impairment and function, and their relationship to demographic, clinical factors, post‐acute sequelae of COVID‐19 (PASC), and biomarkers.
Methods
A total of 128 post‐acute COVID‐19 patients (age = 46 ± 15; 42% women, acute disease severity: not hospitalized: 38.6% mild: 0–1 symptoms, 52% 2+ symptoms; 9.4% hospitalized) completed standard cognition, olfaction, and mental health examinations 2‐, 4‐, and 12‐month post diagnosis. Over the same time frame, WHO‐defined PASC was determined. Blood cytokines, peripheral neurobiomarkers, and kynurenine pathway (KP) metabolites were measured. Objective cognitive function was demographically/practice corrected, and impairment prevalence was determined using the evidence‐based Global Deficit Score method to detect at least mild cognitive impairment (GDS > 0.5). Linear mixed effect regression models with time effect (month post diagnosis) evaluated the relationships to cognition.
Results
Across the 12‐month study period, mild to moderate cognitive impairment ranged from 16% to 26%, and 46.5% were impaired at least once. Impairment associated with poorer work capacity ( p < 0.05), and 2‐month objectively tested anosmia ( p < 0.05). PASC with ( p = 0.01) and without disability ( p < 0.03) associated with acute COVID‐19 severity. KP measures showed prolonged activation (2 to 8 months) ( p < 0.0001) linked to IFN‐beta in those with PASC. Of the blood analytes, only the KP metabolites (elevated quinolinic acid, 3‐hydroxyanthranilic acid, kynurenine, the kynurenine/tryptophan ratio) associated ( p < 0.001) with poorer cognitive performance and greater likelihood of impairment. PASC, independent of disability associated with abnormal kynurenine/tryptophan ( p < 0.03).
Interpretation
The kynurenine pathway relates to post‐acute COVID‐19 objective cognitive impairment and PASC, thereby enabling biomarker and therapeutic possibilities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Peter Duncan Neuroscience Research Unit, St. Vincent's Centre for Applied Medical Research, Darlinghurst, New South Wales, Australia.
- School of Psychology, UNSW, Sydney, New South Wales, Australia.
- Neurology Department, St. Vincent's Hospital, Darlinghurst, New South Wales, Australia.
- School of Psychology, Macquarie University, Sydney, New South Wales, Australia.
- Macquarie Medical School, Macquarie University, Sydney, New South Wales, Australia.
- PANDIS.org, Sydney, New South Wales, Australia.
ORCID-Profile: Bruce J Brew
Förderung
- National Health and Medical Research Council
Zitieren
APA
Cysique, L. A., Jakabek, D., Bracken, S. G., Allen-Davidian, Y., Heng, B., Chow, S., Dehhaghi, M., Staats Pires, A., Darley, D. R., Byrne, A., Phetsouphanh, C., Kelleher, A., Dore, G. J., Matthews, G. V., Guillemin, G. J., & Brew, B. J. (2023). The kynurenine pathway relates to post‐acute COVID ‐19 objective cognitive impairment and PASC. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.51825
Vancouver
Cysique LA, Jakabek D, Bracken SG, Allen-Davidian Y, Heng B, Chow S, et al. The kynurenine pathway relates to post‐acute COVID ‐19 objective cognitive impairment and PASC. Annals of Clinical and Translational Neurology. 2023. doi:10.1002/acn3.51825
BibTeX
@article{Cysique2023,
author = {Cysique, Lucette A and Jakabek, David and Bracken, Sophia G and Allen-Davidian, Yasmin and Heng, Benjamin and Chow, Sharron and Dehhaghi, Mona and Staats Pires, Ananda and Darley, David R and Byrne, Anthony and Phetsouphanh, Chansavath and Kelleher, Anthony and Dore, Gregory J and Matthews, Gail V and Guillemin, Gilles J and Brew, Bruce J},
title = {The kynurenine pathway relates to post‐acute COVID ‐19 objective cognitive impairment and PASC},
journal = {Annals of Clinical and Translational Neurology},
year = {2023},
doi = {10.1002/acn3.51825}
}
EUVIMED